Raffles Medical Group Ltd

Raffles Medical Group Ltd maintains a strong liquidity position, with a current ratio of 1.31 and cash and equivalents amounting to SGD 272.28 million, which supports its short-term obligations. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Free cash flow of SGD 59.33 million and operating cash flow of SGD 101.33 million further reinforce its liquidity and operational efficiency. In terms of profitability, the company's return on equity (ROE) is 6.67%, and return on assets (ROA) is 4.94%, both of which are in line with industry norms for healthcare providers. Operating income of SGD 90.36 million and net income of SGD 70.57 million reflect a healthy margin structure, with gross profit of SGD 664.19 million supporting these results. The company's revenue is concentrated in its core healthcare services and biotechnology segments, with no disclosed geographic diversification beyond its primary market. This concentration may expose the company to regional economic or regulatory shifts, though no immediate risks are flagged in the current risk assessment. Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant revenue deltas expected in the current or next fiscal year. Analysts have assigned a mean price target of SGD 1.25, with a median of SGD 1.25 and a high of SGD 1.30, suggesting a consensus on moderate upside potential. Risk factors for Raffles Medical Group Ltd are currently low, with no immediate liquidity or dilution concerns identified. The company's capital structure remains stable, and no dilution sources have been disclosed in recent filings or transcripts. Recent events, including analyst estimates and price targets, indicate a generally positive outlook from the investment community. The company has not disclosed any major strategic shifts or capital-raising activities in the latest available data.